Background-Although inducible nitric oxide synthase (iNOS) is known to impart powerful protection against myocardial infarction, the mechanism for this salubrious action remains unclear. Methods and Results-Adenovirus-mediated iNOS gene transfer in mice resulted 48 to 72 hours later in increased expression not only of iNOS protein but also of heme oxygenase (HO)-1 mRNA and protein; HO-2 protein expression did not change. iNOS gene transfer markedly reduced infarct size in wild-type mice, but this effect was completely abrogated in HO-1 Ϫ/Ϫ mice. At 48 hours after iNOS gene transfer, nuclear factor-B was markedly activated. In transgenic mice with cardiomyocyte-restricted expression of a dominant negative mutant of IB␣ (IB␣ S32A,S36A ), both basal HO-1 levels and upregulation of HO-1 by iNOS gene transfer were suppressed. Chromatin immunoprecipitation analysis of mouse hearts provided direct evidence that nuclear factor-B subunits p50 and p65 were recruited to the HO-1 gene promoter (Ϫ468 to Ϫ459 bp) 48 hours after iNOS gene transfer. Conclusions-This study demonstrates for the first time the existence of a close functional coupling between cardiac iNOS and cardiac HO-1: iNOS upregulates HO-1 by augmenting nuclear factor-B binding to the region of the HO-1 gene promoter from Ϫ468 to Ϫ459 bp, and HO-1 then mediates the cardioprotective effects of iNOS. These results also reveal an important role of nuclear factor-B in both basal and iNOS-induced expression of cardiac HO-1. Collectively, the present findings significantly expand our understanding of the regulation of cardiac HO-1 and of the mechanism whereby iNOS exerts its cardioprotective actions. (Circulation. 2009;120:1222-1230.)
E xtensive evidence indicates that the inducible isoform of nitric oxide synthase (iNOS) is a major cardioprotective protein. 1, 2 A large number of studies have shown that cardiac overexpression of iNOS confers a protected phenotype and that iNOS is an obligatory mediator of the infarct-sparing effects of the late phase of preconditioning induced by ischemia and several other stimuli, which indicates that upregulation of this enzyme is a common pathway whereby the heart adapts to stress. 3 Consistent with these facts, iNOS gene transfer protects the myocardium from ischemia/ reperfusion injury. 4, 5 Because iNOS has traditionally been viewed as a deleterious enzyme, 2 these results may appear puzzling and raise the question of the mechanism of iNOS-dependent cardioprotection. 6 At present, the molecular basis for the salubrious effects of iNOS remains incompletely understood and represents a major unresolved issue in ischemic biology.
Clinical Perspective on p 1230
One possible explanation for the unexpected beneficial role of iNOS in myocardial ischemia/reperfusion injury is that it might involve the ubiquitously cytoprotective protein heme oxygenase (HO)-1. HO is the rate-limiting enzyme in heme catabolism; it catalyzes the breakdown of heme into equimolar amounts of carbon monoxide, biliverdin, and free iron. 7 Three mammalian HO isoforms have been identified, one of which, HO-1, is a stress-responsive protein induced by a remarkably vast panoply of stimuli. [7] [8] [9] [10] Of the metabolites generated by HO-1 catalysis, biliverdin (and bilirubin) has been shown to possess antioxidant activity, whereas carbon monoxide has been found to exert many salutary effects in various settings, including myocardial ischemia. 7, 11, 12 Although induction of HO-1 is known to constitute a common adaptive response that increases cellular resistance to oxida-tive injury and other types of injury, 7, 12, 13 the role of HO-1 in the cardioprotection afforded by iNOS gene therapy remains unclear.
HO-1 is regulated primarily at the transcriptional level. 7, 14, 15 HO-1 gene expression is mediated through cis-regulatory DNA sequences located in the promoter region, 16 a process that frequently involves transcriptional or structural activation of transcription factors and their translocation to the nucleus. 17 Among them, the presence of nuclear factor (NF)-B-binding sequences in the HO-1 gene promoter region implicates NF-B in the regulation of the HO-1 gene. 18, 19 Because we have previously found that cardiac NF-B is activated by NO in vivo, 20 it appears plausible that augmented NO availability may lead to HO-1 gene expression via NF-B activity.
On the basis of these considerations, we postulated that the cardioprotection afforded by iNOS may be mediated by induction of HO-1 via increased binding of NF-B to the HO-1 gene promoter. To test this hypothesis, we combined molecular analyses with physiological studies in a wellcharacterized murine model of infarction. 21 We examined 3 issues: (1) Whether iNOS gene transfer induces HO-1 expression in the myocardium; (2) if so, whether HO-1 is necessary for the protection afforded by iNOS gene transfer; and (3) whether iNOS regulates HO-1 expression by modulating the access of NF-B to the HO-1 gene promoter. We used iNOS gene transfer to study the mechanism of iNOS-dependent protection because this approach enabled us to achieve selective upregulation of iNOS without the numerous cellular perturbations associated with ischemic preconditioning or other interventions known to induce this protein. 1 Furthermore, we used genetically engineered mice rather than pharmacological agents. That is, to conclusively establish whether HO-1 plays an obligatory role in the cardioprotection afforded by iNOS gene transfer, we studied mice with targeted disruption of the HO-1 gene (HO-1 Ϫ/Ϫ ). 22 To investigate whether the upregulation of HO-1 induced by iNOS gene transfer is mediated by NF-B activity, we used IB␣ mutant transgenic mice with cardiac-specific abrogation of NF-B activation. 23 Finally, to specifically identify NF-B binding to the region of the HO-1 gene promoter, we developed, for the first time, a technique that enabled us to perform chromatin immunoprecipitation (ChIP) analysis directly on the mouse heart.
Methods
This study was performed in accordance with the Guide for the Care and Use of Laboratory Animals (DHHS publication No. 85-23, revised 1996) 
Genetically Engineered Mice
The HO-1 Ϫ/Ϫ mice used in the present study were generated by Yet et al 22 ; colonies were maintained by breeding HO-1 Ϫ/Ϫ males with HO-1 Ϫ/Ϫ females. Offspring were genotyped at the time of weaning by polymerase chain reaction to amplify the wild-type (WT) and mutant alleles of genomic DNA from tail DNA samples. WT littermates were used as controls. Transgenic mice that express a phosphorylation-resistant mutant of IB␣ (IB␣ S32A,S36A ) under the control of a cardiac-specific promoter have been described previously; 23 in these mice, expression of the dominant negative mutant IB␣ results in cardiomyocyte-restricted inhibition of NF-B activation. 23 IB␣ S32A,S36A transgenic mice (IB␣ S32A,S36A Tg) were identified by polymerase chain reaction-based DNA screening. 23 Nontransgenic littermates were used as controls. For all experiments, mice were maintained in microisolator cages under specific pathogen-free conditions in a room with a temperature of 24°C, 55% to 65% relative humidity, and a 12-hour light-dark cycle.
Adenoviral Vectors
Recombinant adenoviral vectors (Av3/LacZ and Av3/iNOS) were constructed essentially as described previously. 4, 5 
In Vivo Gene Transfer
Anesthetized mice received an intramyocardial injection in the anterior left ventricular wall of Av3/LacZ or Av3/iNOS. Two or 3 days later, mice were euthanized for cardiac tissue collection or underwent the infarction protocol summarized below ( Figure 1 ). 4, 5 
Assessment of Infarct Size
Myocardial infarction was produced as described previously ( Figure 1 ). 4, 21, 24 
Western Immunoblotting Analysis, Immunohistochemistry, and Bilirubin Assay
The methods for these procedures are described in the online-only Data Supplement.
Reverse-Transcription Polymerase Chain Reaction Study
For first-strand complementary DNA synthesis and polymerase chain reaction amplification with the One-Step Platinum Taq RT-PCR kit (Invitrogen, San Diego, Calif), 0.1 g of total RNA was used. 25 A 360-bp fragment (for HO-1) or a 494-bp fragment (for GAPDH) was amplified with mouse HO-1-or GAPDH-specific primers. Each sample was assayed in duplicate. On day 1, mice were subjected to intramyocardial injections of Av3/LacZ (LacZ group) or Av3/ iNOS (iNOS group). On day 2 or 3, mice were euthanized for cardiac tissue collection or underwent a 30-minute coronary occlusion followed by 4 hours of reperfusion for the infarct study. NTg indicates nontransgenic mice; IB␣ S32A,S36A Tg, IB␣ S32A,S36A mutant transgenic mice.
ChIP Analysis of Cardiac Tissue
ChIP analysis was performed by use of a magnetic bead-based ChIP kit (Active Motif, Carlsbad, Calif) according to the manufacturer's instructions. 26 Each sample was assayed in duplicate.
Statistical Analysis
Data are reported as meanϮSEM. Protein band density was normalized to the corresponding loading control and then to the mean of the corresponding control group. 4, 24 All data are analyzed with a 1-way or 2-way ANOVA, as appropriate, followed by Student t tests. Because of the small sample sizes, data were also analyzed with nonparametric tests (Kruskal-Wallace test and Mann-Whitney test); because the results were similar to those obtained with 1-way or 2-way ANOVA and Student t tests, for the sake of simplicity and clarity, the latter (parametric) results are reported herein. A P value Ͻ0.05 was considered statistically significant. All statistical analyses were performed with the SigmaStat software system (3.5V).
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results Exclusions
A total of 105 mice were used for the present study: 57 for studies of infarct size, 32 for studies of protein expression, 8 for studies of HO-1 mRNA expression, and 8 for ChIP analyses of NF-B. Twenty-two mice died during or shortly after the surgical procedure, and 8 were excluded because of technical problems. Thus, a total of 75 mice were included in the final analyses.
Fundamental Physiological Parameters
Heart rate and body temperature, fundamental physiological parameters that may impact infarct size, 21 were similar in all 4 groups of mice used for studies of coronary occlusion (Table) . By experimental design, 21, 27 rectal temperature remained within a narrow, physiological range (36.8°C to 37.1°C) in all groups. Five minutes before the 30-minute coronary occlusion, the average heart rate in the 4 groups ranged from 546Ϯ21 to 585Ϯ19 bpm (PϾ0.05). Heart rate did not differ significantly among the 4 groups at any time during the 30-minute occlusion or the ensuing reperfusion (Table) . The size of the region at risk, expressed as a percentage of left ventricular weight, did not differ among the 4 groups: WTϩAv3/LacZ, 41Ϯ1%; WTϩAv3/iNOS, 41Ϯ2%; HO-1 Ϫ/Ϫ ϩAv3/LacZ, 37Ϯ3%; and HO-1 Ϫ/Ϫ ϩAv3/ iNOS, 38Ϯ2% (PϾ0.05).
Effects of iNOS Gene Transfer on HO-1 mRNA, HO-1 Protein, and Bilirubin
Three days after iNOS gene transfer, immunoblotting revealed a marked increase in myocardial iNOS protein expression (ϩ186% versus the LacZ group, nϭ6, Pϭ0.009; Figure  2 ). At the same time, the iNOS-transduced myocardial region also exhibited a significant increase in HO-1 protein expression (ϩ263% versus the LacZ group, nϭ6, Pϭ0.041; Figure  2 ). Consistent with the immunoblotting data, immunohistochemical analysis showed elevated expression of HO-1 (Figure 3C ) and iNOS ( Figure 3F ) in the transduced region of the anterior left ventricular wall 3 days after iNOS gene transfer. Figure 3C and 3F illustrate 2 adjacent sections from the same heart and show that the spatial distribution of HO-1 immunoreactivity coincided with that of iNOS immunoreactivity. At higher magnification (ϫ300), intense HO-1 ( Figure 3B ) 
Data are meanϮSEM. and iNOS ( Figure 3E ) immunoreactivity can be appreciated in cardiac myocytes but not in nonmyocytes. As illustrated in Figure 4 , at 48 hours after iNOS gene transfer, there was a marked elevation in cardiac HO-1 mRNA levels (ϩ212%, nϭ4, versus LacZ group, nϭ3; Pϭ0.003). 
Effect of iNOS Gene Transfer on Infarct Size in HO-1 ؊/؊ Mice
In WT mice, 3 days after Av3 injection, infarct size was reduced by an average of 50% in the Av3/iNOS-treated versus the Av3/LacZ-treated group ( Figure 5 ). In contrast, when HO-1 Ϫ/Ϫ mice received Av3/iNOS, infarct size (47.5Ϯ3.4% of the risk region, nϭ9) did not differ significantly from that observed in HO-1 Ϫ/Ϫ mice that received Av3/LacZ (51.9Ϯ3.3%, nϭ8; Figure 5 ), which demonstrates that HO-1 plays an obligatory role in the cardioprotection afforded by iNOS gene transfer. After LacZ gene transfer, infarct size was similar in HO-1 Ϫ/Ϫ and WT mice ( Figure 5 ), which implies that HO-1 does not modulate ischemia/reperfusion injury under basal conditions. 
Effect of iNOS Gene Transfer on NF-B Nuclear Translocation
Nuclear proteins extracted from the transduced myocardium were assayed for the presence of the active p50 or p65 subunit of NF-B in the nuclear fraction. Quantitative analysis of Western immunoblotting demonstrated increased nuclear content of NF-B at 48 hours after injection of Av3/iNOS with regard to both the p50 subunit (ϩ58.1Ϯ1.3%, nϭ3, versus the LacZ group, nϭ3; PՅ0.001; Figure 6 ) and the p65 subunit (ϩ52.1Ϯ1.9%, nϭ3, versus the LacZ group, nϭ3; PՅ0.001; Figure 6 ).
Effect of iNOS Gene Transfer on HO-1 Protein Expression in IB␣ S32A,S36A Mutant Transgenic Mice
Consistent with the results reported above, nontransgenic mice that received Av3/iNOS exhibited robust expression of HO-1 in the transduced myocardium (Figure 7 ). On average, injection of Av3/iNOS in nontransgenic mice resulted in a 2.2-fold increase in HO-1 protein content versus Av3/LacZtreated nontransgenic mice. In contrast, myocardial HO-2 protein expression did not change after iNOS gene transfer (nϭ3; Figure 7 ). Interestingly, HO-1 immunoreactivity was weaker in the transduced myocardium of IB␣ S32A,S36A mutant transgenic mice treated with Av3/LacZ than in nontransgenic mice under the same conditions (Ϫ60% versus the nontransgenicϩAv3/LacZ group, nϭ3; Pϭ0.019; Figure 7 ) and in IB␣ S32A,S36A mutant transgenic mice not subjected to iNOS gene transfer versus the corresponding nontransgenic mice (Ϫ38%, nϭ3; online-only Data Supplement Figure I) , which suggests that NF-B modulates cardiac HO-1 protein expression under basal conditions. Although in IB␣ S32A,S36A mutant transgenic mice subjected to iNOS gene transfer HO-1 was still upregulated relative to IB␣ S32A,S36A mutant transgenic mice treated with Av3/LacZ, levels of HO-1 expression were much lower than in nontransgenic mice treated with Av3/iNOS (Ϫ56% versus the nontransgenicϩAv3/iNOS group, nϭ3; Pϭ0.036; Figure 7 ), which indicates that NF-B plays an essential role not only in basal cardiac HO-1 protein expression but also in iNOS-dependent induction of HO-1. The increase in HO-1 in IB␣ S32A,S36Ad Tg mice treated with Av3/iNOS (Figure 7 ) likely reflects the multifactorial nature of HO-1 regulation 14, 18 and the activation by NO of transcription factors other than NF-B. In principle, it may also reflect synthesis of HO-1 in noncardiac myocytes (because the mutant IB␣ is expressed selectively in cardiac myocytes 23 ). However, as indicated above, immunohistochemical analysis confirmed that induction of HO-1 by iNOS gene transfer occurred in cardiac myocytes (Figure 3 ).
Effect of iNOS Gene Transfer on NF-B Binding to the HO-1 Gene Promoter
To further investigate the mechanism whereby iNOS modulates HO-1, we used a ChIP method that enabled us to directly assess the effect of iNOS gene transfer on the upstream regulatory sequences of the HO-1 gene in cardiac tissue. As shown in Figure 8 , ChIP analysis demonstrated that 48 hours after iNOS gene transfer, NF-B was recruited to the HO-1 gene promoter (specifically, to the region from Ϫ468 to Ϫ459 bp), as evidenced by the presence of both the p50 subunit (ϩ230% versus the LacZ group, nϭ3; PՅ0.001) and the p65 subunit (ϩ179% versus the LacZ group, nϭ3; PՅ0.001), a finding consistent with the observation that iNOS enhances HO-1 mRNA levels (Figure 4) . These results suggest that an NF-B binding element located in the Ϫ468to Ϫ459-bp region of the murine HO-1 gene promoter is involved in the transcriptional activation of the HO-1 gene in response to iNOS gene transfer. 
Discussion
Although studies of ischemic preconditioning 1, 27 and iNOS gene transfer 4, 5, 24 have clearly shown that iNOS imparts powerful protection against myocardial infarction, the mechanism of this salubrious action remains unclear. iNOS is upregulated by numerous and diverse stimuli and thus appears to be a ubiquitous cardioprotective protein. 2 Of similar potential importance is HO-1, another cytoprotective enzyme that has been recognized to play a critical role in response to various forms of stress, including myocardial ischemia. 28 -31 At present, virtually nothing is known about the interaction between these 2 major protective systems in the myocardium and the molecular mechanism whereby iNOS modulates cardiac HO-1. The present study provides considerable new information relevant to these issues. Our salient findings can be summarized as follows: (1) iNOS gene transfer upregulates not only cardiac levels of iNOS protein but also those of HO-1 mRNA and protein, which indicates that in the heart, HO-1 is coupled to iNOS;
(2) targeted disruption of the HO-1 gene completely abrogates the infarct-sparing effects of iNOS gene transfer, which demonstrates that HO-1 is a necessary mediator of iNOSdependent cardioprotection; (3) iNOS gene transfer promotes translocation of NF-B to the nucleus and its binding to a specific element in the promoter region of the HO-1 gene, as demonstrated by both Western immunoblotting and ChIP analysis of cardiac tissue, which suggests that the molecular mechanism whereby iNOS controls HO-1 expression involves transcriptional activation of HO-1 via an NF-Bdependent pathway; and (4) cardiac-specific abrogation of NF-B activation via expression of a dominant negative mutant of IB␣ (IB␣ S32A,S36A ) suppresses the HO-1 upregulation elicited by iNOS gene transfer and diminishes basal levels of HO-1 expression, which demonstrates that NF-B is essential for cardiac HO-1 protein expression under basal conditions and for the induction of HO-1 by iNOS.
Previous investigations have shown that iNOS and HO-1 exert a multitude of cytoprotective effects. 1, 2, [27] [28] [29] [30] [31] [32] [33] To the best of our knowledge, however, this is the first study to demonstrate the existence of a tight coupling between cardiac iNOS and cardiac HO-1, 2 inducible proteins that play a critical role in the response of the heart to ischemia and other forms of stress. This is also the first study to identify NF-B activation as a key mechanism that mediates iNOS-dependent modulation of HO-1 in the heart.
Role of HO-1 in the Cardioprotection Afforded by iNOS
Mounting evidence indicates that HO-1 plays an important cytoprotective role. 28, [33] [34] [35] This enzyme has been found to have beneficial effects in a wide variety of pathological conditions, such as inflammation, atherosclerosis, and ischemia/reperfusion injury. 28, 33, 34 In noncardiac tissues, there is evidence that HO-1 is regulated by NO 36, 37 among other factors, and on this basis, we postulated that iNOS may activate HO-1 in the heart. Although iNOS can be induced by many stimuli, including ischemic preconditioning, 2 we elected to use iNOS gene transfer to study iNOS-dependent modulation of HO-1 because this approach results in selective upregulation of iNOS (Figures 2 and 3 ) and thus in a sustained increase in myocardial NO production without the confounding effects of the multifarious cellular perturbations and changes in gene expression that are associated with ischemia/reperfusion or with pharmacological manipulations. 1 As a consequence, the effect of NO on cardiac HO-1 can be assessed independent of other cellular changes and in the setting of a relatively steady-state NO generation. Indeed, we 4 have previously demonstrated that concomitant with the elevation of iNOS protein expression, nitrate and nitrite levels are increased significantly 3 days after iNOS gene transfer in the transduced myocardium but not in the serum, which indicates that the source of NO is cardiac. Our present findings that the increased myocyte expression of iNOS was associated with increased myocyte expression of HO-1 protein (Figures 2 and 3 ) and mRNA ( Figure 4 ) and with increased content of bilirubin (a byproduct of HO-1), as well as that iNOS and HO-1 were colocalized in the same myocardial region that received iNOS gene transfer ( Figure  3) , reveal a heretofore unrecognized coupling between the iNOS and HO-1 systems in the heart, even in the absence of ischemic stress or other pathological conditions. The mere fact that iNOS expression is associated with HO-1 upregulation, however, does not necessarily imply a functional role of HO-1 in iNOS-dependent effects, because HO-1 upregulation may simply be an epiphenomenon. Clearly, elucidation of the role of HO-1 in iNOS-dependent protection requires inhibition of HO-1 activity. This could be achieved pharmacologically, but the utility of HO-1 inhibitors is limited by their relative lack of specificity. 38, 39 Consequently, we used a molecular-genetic approach by studying mice with targeted disruption of the HO-1 gene. The similarity in infarct size between WT and HO-1 Ϫ/Ϫ mice after Av3/LacZ administration ( Figure 5 ) implies that HO-1 does not play a significant cardioprotective role under basal conditions, possibly because of its low level of expression in normal myocardium (Figure 7) . However, the fact that HO-1 gene knockout ablated the infarct-sparing effects of iNOS gene transfer ( Figure 5 ) provides conclusive evidence that upregulation of HO-1 is necessary for the acquisition of ischemic tolerance afforded by iNOS and that HO-1 is an obligatory mediator of iNOS-dependent protection. Thus, an increase in iNOS in itself (in the absence of ischemia or other stimuli) is sufficient to induce myocardial HO-1 expression in vivo, which reveals a new aspect of the regulation of cardiac HO-1. On the basis of these observations, we propose that a close functional coupling exists between cardiac iNOS and cardiac HO-1 and that induction of HO-1 is a critical mechanism responsible for the cardioprotective effects of iNOS. Inasmuch as iNOS appears to be a common mediator of the protection induced by various types of preconditioning, 1 this concept implies that HO-1 plays a major role in these adaptations as well.
Role of NF-B in iNOS-Dependent Upregulation of HO-1
The mechanism whereby iNOS induces expression of HO-1 in the heart is unknown. One of the major transcription factors known to govern HO-1 expression is NF-B, 40 which has also been implicated in the cardioprotection afforded by iNOS gene therapy. 24 At present, however, nothing is known about whether NF-B is involved in iNOS-dependent modulation of cardiac HO-1.
NF-B is most commonly a heterodimer of p50 and p65 and is maintained in an inactive state in the cytoplasm by IB␣. 41 In response to various stresses, phosphorylation of the serine residues at positions 32 and 36 results in degradation of IB␣, which allows NF-B to translocate to the nucleus and activate NF-B-dependent genes. 23, 41 To overcome the limitations inherent in pharmacological manipulations of NF-B, we have created a transgenic mouse that expresses cardiac-specifically a dominant negative mutant IB␣ protein in which both serine residues 32 and 36 are replaced by alanine (IB␣ S32A,S36A ). 23 These IB␣ S32A,S36A mutant transgenic mice exhibit normal cardiac development, morphology, and histology. 23, 24 The effectiveness of NF-B suppression is demonstrated by the fact that tumor necrosis factor-␣ and lipopolysaccharide, 2 of the most potent stimuli known to activate NF-B, 42 fail to increase its nuclear levels in IB␣ S32A,S36A mutant transgenic mice. 23, 24 To gain insights into the role of NF-B in iNOS-dependent modulation of HO-1, we first examined the nuclear content of NF-B at 48 hours after iNOS gene transfer. Our finding of increased nuclear content of p50 and p65 ( Figure 6 ) is consistent with our previous observation that iNOS gene transfer results in increased phosphorylation of IB␣ at serine residues 32 and 36 and increased NF-B DNA binding activity in the nuclear fraction. 24 The finding that cardiomyocyterestricted abrogation of NF-B activation in IB␣ S32A,S36A mutant transgenic mice given Av3/LacZ significantly reduced basal levels of cardiac HO-1 protein expression compared with nontransgenic mice given Av3/LacZ (Figure 7) implies that NF-B modulates cardiac HO-1 protein expression under basal conditions. The observation that upregulation of HO-1 protein expression by iNOS gene transfer in nontransgenic mice was blocked in IB␣ S32A,S36A Tg mice (Figure 7 ) demonstrates that NF-B is obligatorily involved in this process. Thus, taken together, these results reveal that NF-B plays an essential role not only in the basal cardiac expression of HO-1 but also in the upregulation of HO-1 by iNOS. Our previous finding that the reduction in infarct size afforded by iNOS gene therapy is abolished in IB␣ S32A,S36A mutant transgenic mice 24 indicates that NF-B is also essential for iNOSdependent protection and that abrogation of the expression of NF-Bdependent genes (among which is HO-1) renders the heart more susceptible to lethal ischemic/reperfusion injury. On the other hand, the fact that HO-2 protein levels were similar in nontransgenic and IB␣ S32A,S36A mutant transgenic mice regardless of iNOS gene transfer (Figure 7) indicates that the increased iNOS expression does not affect cardiac HO-2 protein and that NF-B is not involved in the regulation of HO-2.
The classic NF-B isoform (a p50 and p65 heterodimer) is capable of binding to the B DNA binding site, a 10-or 11-bp sequence. 43 The present ChIP analysis identified, in the intact mouse, a specific DNA element (GGGTTTGCCC) located upstream of the transcription initiation site of the mouse cardiac HO-1 gene (from Ϫ468 to Ϫ459 bp) that binds both the p50 and p65 subunits (Figure 8 ), which provides a molecular substrate for the upregulation of the HO-1 gene by iNOS. To the best of our knowledge, this is the first study to use ChIP analysis in the mouse heart, a powerful approach for identifying transcription factors associated with specific regions of the target gene promoter. 26 
Conclusions
We have used ChIP analysis of intact cardiac tissue combined with a genetically molecular approach in a well-established and physiologically relevant murine model of infarction. With this approach, we have demonstrated for the first time that iNOS modulates the expression of HO-1 in the heart by augmenting NF-B nuclear localization and binding to the HO-1 gene promoter, resulting in increased transcription of the HO-1 gene. The present data indicate that NF-B activation is important both for basal levels of cardiac HO-1 protein expression and for iNOS-dependent upregulation of HO-1. We have also shown that HO-1 plays an obligatory role in the cardioprotection afforded by iNOS gene therapy. The present findings significantly expand our understanding of the regu-lation of cardiac HO-1 and of the mechanism whereby iNOS exerts its cardioprotective effects. The data reveal the existence of an iNOS-HO-1 cardioprotective module in which these proteins effectively function together to limit myocardial ischemia/reperfusion injury.
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